DEI Special Edition Spring / Summer 2024
• Poor Generalizability: Clinical trials with a lack of diverse partici- pants may not accurately represent the real - world prevalence of a given health condition, leading to limited applicability of the results. • Ineffective or Harmful Treatments: The lack of diversity in clinical trials can result in drugs and treatments that are less effective or even harmful for certain groups. • Increased Health Disparities: The lack of representation of racial and ethnic minority groups in clinical research can contribute to health disparities and widen existing health inequities. • Post - Market Issues: As listed above the FDA has encountered issues with post - market use of approved drugs due to insufficient diversity in clinical trials. • Economic Costs : The lack of diversity in clinical trials unfairly skews medicine and costs billions of dollars a year in early deaths and poor health. • The Ripple Effect on Public Health: The lack of diversity in clinical trials is not a mere procedural flaw; it has tangible consequences for public health.
ONGOING CHALLENGE: Despite the lessons learned and increasing awareness regarding the potential consequences, the underrepresentation of certain demographics in clinical trials persists. Women, older adults, racial and ethnic minorities, and individuals with multiple health conditions are often underrepresented, hindering our ability to under- stand the nuanced responses to medical interventions.
39
Made with FlippingBook - professional solution for displaying marketing and sales documents online